AMED Amedeo Res

RNS No 949c
CHIROSCIENCE GROUP PLC
19th September 1997
 
 
  LEVOBUPIVACAINE: NEW DATA PRESENTED AT XVIth ANNUAL CONGRESS
         OF THE EUROPEAN SOCIETY OF REGIONAL ANAESTHESIA
 
Chiroscience  Group  plc  last  night  presented  new  data   on
levobupivacaine,  the  long acting local anaesthetic,  which  is
progressing  through  Phase  III  trials  towards  the   planned
European  regulatory filing in December 1997 and  US  filing  in
April 1998.
 
Investigators   summarised   key   pre-clinical   and   clinical
experience  to  date  for  levobupivacaine  during  a  satellite
symposium  at the XVIth Annual Congress of the European  Society
of   Regional   Anaesthesia  (London,  18th   September   1997).
Significant new clinical results were presented in the key areas
of major surgery and post-operative pain management.
 
Clinical  investigations using levobupivacaine to provide  post-
operative pain control were reported by Dr James C. Crews of the
Bowman  Gray School of Medicine, North Carolina. In a  trial  of
patients   undergoing   lower  limb   orthopaedic   surgery,   a
combination of levobupivacaine and fentanyl was compared to both
drugs   used  alone.   In  a  second  trial  involving  patients
undergoing  major  abdominal surgery, the pain control  achieved
with  a combination of levobupivacaine and morphine was compared
to that of each drug used in isolation.
 
The  results  of both trials clearly demonstrated the  value  of
combining  either morphine or fentanyl with levobupivacaine  for
post-operative pain control.  In addition, the total amounts  of
supplementary analgesia required for effective pain control were
reduced. While bupivacaine is not approved in the USA for  post-
operative  pain management, this data supports such a new  claim
for levobupivacaine.
 
Dr Dan J. Kopacz, of the Virginia Mason Medical Center, Seattle,
reported  the  results  of  trials in  major  surgery  comparing
levobupivacaine  with  bupivacaine  using  a  variety  of  block
techniques.   Levobupivacaine  was  equivalent  in  potency   to
bupivacaine, with a slightly faster onset and slower  offset  of
pain  relief,  but  with the same depth  of  anaesthesia  and  a
slightly  shorter  duration  of  motor  block.   These  results,
combined  with  the growing evidence of levobupivacaine's  lower
cardiovascular  and  central nervous system side  effects,  show
that  levobupivacaine  could be used as  a  safer,  but  equally
effective, agent than bupivacaine for regional anaesthesia.
 
Other  presentations  at  the  symposium  reviewed  the  use  of
levobupivacaine  in obstetric anaesthesia, its neuropharmacology
and   its  cardiovascular  and  central  nervous  system  safety
profiles in pre-clinical models.  The studies reported are among
the  first  of a wide range of trials nearing completion,  which
will  be  used to support levobupivacaine's regulatory  filings.
Additional  new data will be presented at the annual meeting  of
the  American  Association of  Anesthesiologists (18-22  October
1997).

For further information contact:
Dr John Padfield, Chief Executive       Giles Sanderson
Andrew Burrows, Media Relations         Financial Dynamics
Rebecca Iveson, Investor Relations      Tel: +44 (0)171 831 3113
Tel: +44 (0)1223 420430      
http://www.chiroscience.com
 
Chiroscience Group plc
 
Chiroscience is an emerging pharmaceutical company operating  in
the  UK  and USA, which uses its diverse technology platform  to
discover  and  develop novel medicines for improved  healthcare.
The  Group  has  two principal activities, operating  as  Darwin
Discovery  and ChiroTech.  Chiroscience is listed on the  London
Stock Exchange.
 
Darwin  Discovery embraces activities in Cambridge, Seattle  and
Stevenage, including gene-based research and molecular  biology,
through   chiral-based,  combinatorial,  medicinal  and  process
chemistries,  to  clinical development.  It is  engaged  in  the
discovery and development of innovative small molecule drugs and
related  diagnostics  with  a therapeutic  focus  on  autoimmune
disease, cancer, inflammation, pain and osteoporosis.
 
ChiroTech  provides  chiral  technology  services  to  customers
within  the pharmaceutical and related industries and in support
of Darwin Discovery's research and development programmes.
                                

END

Grafico Azioni Amedeo Res (LSE:AMED)
Storico
Da Giu 2024 a Lug 2024

Grafico Azioni Amedeo Res (LSE:AMED)
Storico
Da Lug 2023 a Lug 2024